CN106539934A - A kind of pharmaceutical composition for treating optic atrophy - Google Patents

A kind of pharmaceutical composition for treating optic atrophy Download PDF

Info

Publication number
CN106539934A
CN106539934A CN201611133177.4A CN201611133177A CN106539934A CN 106539934 A CN106539934 A CN 106539934A CN 201611133177 A CN201611133177 A CN 201611133177A CN 106539934 A CN106539934 A CN 106539934A
Authority
CN
China
Prior art keywords
weight
extract
ethanol
pharmaceutical composition
weight portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201611133177.4A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Haoyu Qingtian Medicine Technology Co ltd
Original Assignee
Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Haoyu Qingtian Medicine Technology Co ltd filed Critical Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority to CN201611133177.4A priority Critical patent/CN106539934A/en
Publication of CN106539934A publication Critical patent/CN106539934A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a kind of treat pharmaceutical composition of optic atrophy and preparation method thereof, pharmaceutical composition of the present invention is galloped along on horseback as bulk drug with wolf beanstalk grass, japanese spicebush bark, asiatic acid, wooden tangerine, black bone, proportioning is formed, routinely various formulations can be made by preparation process, treatment optic atrophy is evident in efficacy.

Description

A kind of pharmaceutical composition for treating optic atrophy
Technical field
The invention belongs to technical field of traditional Chinese medicines, more particularly to a kind of pharmaceutical composition for treating optic atrophy and its preparation Method.
Background technology
Optic atrophy is in the presence of some diseases or paathogenic factor to send out retinal ganglial cells and its aixs cylinder Sick change, finally makes optic nerve all attenuate.In terms of ophtalmic treatments, Eye injuries cause optic atrophy to belong to one of difficult disease, are Clinically relatively conventional illness, there is no specific treatment at present in treatment.Especially the patient long to post burn be more It is that curative effect is little.
Among the various causes of disease of blinding, eye traumas is in occupation of main positions.When eye socket occurs bone in the presence of external force Folding or wounding, in the presence of the blunt forces such as boxing injury oppression eyeball so as to when Posterior pole retina train of thought oedema is gushed out, can cause Optic nerve is oppressed, and this exactly causes the one of the main reasons of optic atrophy.Optic nerve is direct in the presence of external force It is injured；Under the influence of some pathologies, optic nerve is destroyed rapidly and is caused its atrophy.Fashion can absorb oedema in the early stage And bleeding, afflicted area is further reduced, makes function be restored.But if necrosing, the permanent of optic nerve is will result in Atrophy, while can also lose correlation function.Observing eye bottom is pale for optic disk at the beginning, and blood vessel attenuates, and is spaced several weeks Can just find that atrophy occurs in nipple afterwards, border is clearly demarcated, and blood vessel is normal.And during the eye traumas of doctor trained in Western medicine causes optic atrophy to refer to Its Chinese pathology mechanism and treatment method are sought in the glaucoma of doctor or collision injury eyeball.Motherland's medical science thinks, passivity external force collision eye, Eyeball is damaged, and then causes body deficiency of qi and blood, makes blood extravasation of blood, overflows outside arteries and veins, or qi and blood stagnation mesh system train of thought, causes born of the same parents The positions such as eyelid, white of the eye, black eyeball or eyeball pearl are injured, occur the symptoms such as visual impairment, diplopia, mesh pain, stasis of blood in the eyelid the eyelid of purple color swelling, bleeding or Sign, if fail treatment in time or occur controlling by mistake, train of thought is obstructed and is increased, it is seen that mesh key is inaccessible, causes anopia.For causing The reason for optic atrophy, invigorating spleen for diuresis, promoting blood circulation and removing blood stasis during tcm syndrome differentiation and treatment, is focused on, such as occur oedema product for qi stagnation blood stasis Liquid, can select activating blood and promoting diuresis method.Aqueous in tissue were blood component originally, and under wound effect, imbalance occurs in zang-fu organs qi movement, Cause blood obstacle, have impact on defeated cloth and the excretion of aqueous to a great extent, after stopping accumulation, form oedema.In view of This, will treat this disease, and needs are conceived to promoting blood circulation while will also take into account Li Shui.
Wooden tangerine：This product is dried immature fruit for rutaceae wood tangerine Aegie marmelos (L.) Correa's.11 ～December gathers, whole or cross-sectional, dries.【Nature and flavor】It is sour, puckery, it is cool.【Function with cure mainly】Antidiarrheal, antiemetic.For hot dysentery, size Arteries and veins heat is rushed down, chronic diarrhea, vomiting.【Proterties】This product is in Long Circle or subsphaeroidal, and surface is blackish green, more smooth.Exocarp is harder, Crisp, section micro-strip is red, and middle pericarp and endocarp are faint yellow, it is seen that 8～15 carpels.Tool turpentine oil sample fragrance, mildly bitter flavor, often Mucus.Record Tibetan medicine standard is issued in the Ministry of Public Health（First）, standard number：WS3-BC-0013-95.
Wolf beanstalk grass：This product is Li Baikemang beanstalk platymiscium iron awns beanstalk Dicranopteris linearis（Burm.f.） Underw. ［ Polypodium lineare Burm.f.；Gleichenia linearis Clarke ］ herb.It is annual Harvesting, cleans, removes fibrous root and petiole, rhizome is separated with leaf, dry.【Nature and flavor】It is bitter；It is sweet；It is flat.【Indication】Hemostasis；Connect Bone；Clearing heat and promoting diuresis；Removing toxicity for detumescence.Main metrorrhagia；Nosebleed epistaxis；Hemoptysis；Traumatism and bleeding；Injury and bone fracture；Puckery pain of heat gonorrhea；Leukorrhea；Rubella scabies Itch；Sore swells；Scald；Hemorrhoid complicated by anal fistula；Snake bite and insect sting；Cough.【Former phytomorph】Iron awns beanstalk, large-scale terrestrial pteridophyte, the high 60- of plant 150cm.Overgrow.Rhizome it is horizontal walk, dark-brown, when young base portion by brown hair, after polish；Five to eight times two fork branches of rachis, one The long 13-16cm of rachis is returned, the pinna rachis of more than two times is shorter, the long 3.5-6cm of rachis is returned at end；Each time axillary bud is avette, close by rust hair； Tool bract, avette, edge tool triangle sliver；In addition to first time bifurcated, there is 1 pair of stipule shape plumage remaining each time crotch both sides Piece, obliquely, the long 12-18cm of bottom, wide 3.2-4cm, top diminish, lanceolar or wide lanceolar；Accessory pinna is returned with support in end Lobate accessory pinna is similar, long 5.5-15cm, wide 2.5-4cm, and comb dentation plumage split is several up to pinna rachis；Sliver 15-40 pair, lanceolar or wire Lanceolar, long 10-18mm, wide 2-3mm are several to minimum, triangle, long 4-6mm on the upside of base portion；Middle arteries are protruding below, lateral vein Tiltedly open up, have scun 3 per group, sporangiorus is circular, tiny, 1 row are born on the upside of base portion at the tortuous bow of scun, by 5-7 spore Ascus constitutes.Record in dictionary of medicinal plant.
Japanese spicebush bark：For Lauraceae Lindera plant Cortex Linderae Obtusilobae Lindera obtusiloba Bl. The bark of [L.cercidifolia Hemsl.].The four seasons can adopt, and dry.【Nature and flavor】It is pungent；Temperature.【Return through】Stomach；Liver Channel.【Function Cure mainly】Middle benefit gas promoting the circulation of qi；Promoting blood circulation to remove blood stasis.Main trusted subordinate's pain；Traumatic injury；Blood stasis and swelling pain；Sore.【Chemical analysis】Trunk contains paddy Sterol, stigmasterol and campesterol (Campesterol).Branches and leaves 0.4-0.6% containing aromatic oil, predominantly l-borneol (Linde- rol).Leaf has the linear paraffin containing carbon number from 16-33.Contain capric acid (Capric acid), laurate (Lauric in seed oil Acid), nutmeg acid (14 (alkane) acid, Myristic acid), cis-dodecenoic acid (Linderic acid, Dodecen-4- Oic acid), decenoic acid (Decenoic acid), obtusilic acid (Decen-4-oic acid, Obtusilic Acid), tetracecen-4-oic acid (Tetradecen-4-oic acid, Tsudzuic acid), oleic acid (Oleic acid) and Asia Oleic acid (Linoleic acid) etc..【Proterties】Bark be in thin drum, long 16-25cm, wide 2cm, thick 1.5-2mm.Outer surface ash Brown, coarse, the irregular thin longitudinal grin of tool and spot block texture, the little hole skin of bossed similar round, cork come off or scrape off after compared with Smooth, brown color is to rufous；Inner surface rufous, flat, it is seen that thin longitudinal grin, that what is drawn shows slightly oil trace.Matter is firmly crisp, plane of rupture compared with It is flat.Outer layer brown color, internal layer rufous and slightly oil.Gas micro-perfume, lightly seasoned, micro-pungent.Record in dictionary of medicinal plant.
Black bone is galloped along on horseback：This product is that Icacinaceae must stamen fogfruit crin wood Gomphandra tetrandra（Wall.et Roxb.）Sleum ［ Lasian theratetrandra Wall.et Roxb.；Gomphandra hainanensis Merr. ］ Root.Whole year can excavate, and clean, and section is dried.【Nature and flavor】It is bitter；It is flat.【Indication】Clearing away damp-heat；Relieving heat toxin.Master is damp and hot Vomit and diarrhoea；Carbuncle sore tumefacting virus.【Former phytomorph】Crin wood shrub or dungarunga, high 2-10m.Bark grey, spray green, then Raw branch is become without hair later by pubescence.Leaf alternate, the long 0.5-1.5cm of petiole, just by pubescence；Leaf papery, narrow lanceolar, length Oval or oblong, long 6-15cm, wide 2-6cm, tip are tapering, base portion wedge shape, full edge, two sides without hair or during children below quilt Faint yellow pubescence, above it is dark green, below slightly weaker, middle arteries overleaf significant protuberance, lateral vein about 6-8 pair, net vein is not obvious.Male and female Different strain, cyme and leaf opposite, armpit life sometimes, long 2-4cm are close by yellow-white pubescence, have common peduncle, the long 0.2- of bennet 0.5cm；Male flower yellow-white or white green, 5 numbers are about 5mm, and corolla is bell, long 3-4mm, the nearly triangle of petal sliver, and length is about The 1/3 of corolla, inward curl, outside is without hair；Stamen 4-5, filigree are longer than corolla；Female flower yellow-white, is about 5mm, calyx micro- 5 Split, it is long less than 5mm；Corolla is bell, is about 0.5mm, and petal sliver Yangtze River Delta shape is curved in tip；Obsolete stamen in female flower Isometric with ovary, ovary is cylindric, and without hair or sometimes by hair, column cap is little, 5 split it is slightly downward in ovary.Drupe is oval, is about 1.2-2.5cm, footpath 0.5-1.2cm, white when ripe, berry shape have obvious vertical rib after doing, and carpopodium is slightly by pubescence.Flower, fruiting period It is annual.Record in dictionary of medicinal plant.
Asiatic acid（Asiatic acid）：CAS 464-92-6, molecular formula C30H48O5, molecular weight 488.70.【It is biological Activity】Help to create new connective tissue;Promote wound healing (external application);Promote epidermal cornified;Granulation is stimulated to occur. 【Ingredient origin】Borneol Dryobalanops aromatics, centella Centella asiatica.
1 bulk drug chemical constitution：
Asiatic acid（Asiatic acid）.
The content of the invention
The purpose of the present invention is to overcome the shortcomings of background technology, there is provided a kind of drug regimen of effectively treatment optic atrophy Thing and preparation method thereof.
The present invention adopts the following technical scheme that realization：
The composition and weight portion for making the bulk drug of the pharmaceutical composition of the treatment optic atrophy be：
Wolf beanstalk grass 922-928 weight portion japanese spicebush bark 582-590 weight portion asiatic acid 15-17 weight portions wood tangerine 162-168 weights Amount part black bone is galloped along on horseback 65-70 weight portions.
The pharmaceutical composition for the treatment of optic atrophy is preferably used in, is made up of the bulk drug of following weight portion：
16 weight portion wood 165 weight portion black bone of tangerine of wolf beanstalk grass 925 weight portion japanese spicebush bark 586 weight portion asiatic acid gallops along on horseback 68 Weight portion.
A kind of pharmaceutical composition for treating optic atrophy, it is characterised in that pharmaceutical composition can adopt the normal of galenic pharmacy Rule method prepares piece agent or capsule or dripping pill.
A kind of pharmaceutical composition for treating optic atrophy, it is characterised in that pharmaceutical composition is constituted with chemical drugs or Chinese medicine Treatment optic atrophy medicine.
A kind of preparation method of the pharmaceutical composition for treating optic atrophy, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：Wolf beanstalk grass 922-928 weight portion japanese spicebush bark 582-590 weight portion asiatic acids 15-17 weight portions wood tangerine 162-168 weight portion black bones are galloped along on horseback 65-70 weight portions；
Preparation method：
（1）Wolf beanstalk grass, japanese spicebush bark, asiatic acid, wooden tangerine, black bone are taken by bulk drug proportioning to gallop along on horseback, is mixed, it is dense with percentage by weight 36.5% ethanol being spent as solvent, being taken in 24.5 DEG C of temperature extractions, extraction time is 12 times, and each extraction time is 0.4 hour, often 27 times for bulk drug gross weight of secondary solvent load, filtration obtain dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into phase To density 1.04, filtration, liquid are first washed with water by H103 large pore resin absorption columns, then with 19% second of weight percent concentration Alcoholic solution elutes H103 large pore resin absorption columns, collects 19% ethanol eluate of weight percent concentration, reclaims ethanol, and concentration is dry It is dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with 78% ethanol of weight percent concentration as solvent, heating and refluxing extraction 5 times, is carried every time The time is taken for 1 hour, 50 times for dregs of a decoction A weight of each solvent load, filtration obtain dregs of a decoction B and extract B, and extract B is reclaimed Ethanol, is concentrated into relative density 1.12, and filtration, liquid are first washed with water, then use weight by XAD-4 large pore resin absorption columns 83% ethanol solution of percent concentration elutes XAD-4 large pore resin absorption columns, collects 83% ethanol eluate of weight percent concentration, Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Preferred a kind of preparation method of the pharmaceutical composition for treating optic atrophy, it is characterised in that make as follows It is standby：
The composition and weight portion of bulk drug be：586 weight portion asiatic acid of wolf beanstalk 925 weight portion japanese spicebush bark of grass, 16 weight portion 165 weight portion black bone of wooden tangerine is galloped along on horseback 68 weight portions；
Preparation method：
（1）Wolf beanstalk grass, japanese spicebush bark, asiatic acid, wooden tangerine, black bone are taken by bulk drug proportioning to gallop along on horseback, is mixed, it is dense with percentage by weight 36.5% ethanol being spent as solvent, being taken in 24.5 DEG C of temperature extractions, extraction time is 12 times, and each extraction time is 0.4 hour, often 27 times for bulk drug gross weight of secondary solvent load, filtration obtain dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into phase To density 1.04, filtration, liquid are first washed with water by H103 large pore resin absorption columns, then with 19% second of weight percent concentration Alcoholic solution elutes H103 large pore resin absorption columns, collects 19% ethanol eluate of weight percent concentration, reclaims ethanol, and concentration is dry It is dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with 78% ethanol of weight percent concentration as solvent, heating and refluxing extraction 5 times, is carried every time The time is taken for 1 hour, 50 times for dregs of a decoction A weight of each solvent load, filtration obtain dregs of a decoction B and extract B, and extract B is reclaimed Ethanol, is concentrated into relative density 1.12, and filtration, liquid are first washed with water, then use weight by XAD-4 large pore resin absorption columns 83% ethanol solution of percent concentration elutes XAD-4 large pore resin absorption columns, collects 83% ethanol eluate of weight percent concentration, Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
A kind of preparation method of the pharmaceutical composition for treating optic atrophy, it is characterised in that pharmaceutical composition can be adopted The conventional method of galenic pharmacy prepares piece agent or capsule or dripping pill.
A kind of preparation method of the pharmaceutical composition for treating optic atrophy, it is characterised in that pharmaceutical composition and chemical drugs Or Chinese medicine composition treatment optic atrophy medicine.
Medicine composite for curing optic atrophy is evident in efficacy.
Specific embodiment
Embodiment 1：Pharmaceutical composition for the treatment of optic atrophy and preparation method thereof
Treatment optic atrophy pharmaceutical composition bulk drug composition and weight portion be：Wolf beanstalk grass 925g japanese spicebush bark 586g Asiatic acid 16g wood tangerine 165g black bones are galloped along on horseback 68g；
Preparation method：
（1）Wolf beanstalk grass, japanese spicebush bark, asiatic acid, wooden tangerine, black bone are taken by bulk drug proportioning to gallop along on horseback, is mixed, it is dense with percentage by weight 36.5% ethanol being spent as solvent, being taken in 24.5 DEG C of temperature extractions, extraction time is 12 times, and each extraction time is 0.4 hour, often 27 times for bulk drug gross weight of secondary solvent load, filtration obtain dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into phase To density 1.04, filtration, liquid are first washed with water by H103 large pore resin absorption columns, then with 19% second of weight percent concentration Alcoholic solution elutes H103 large pore resin absorption columns, collects 19% ethanol eluate of weight percent concentration, reclaims ethanol, and concentration is dry It is dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with 78% ethanol of weight percent concentration as solvent, heating and refluxing extraction 5 times, is carried every time The time is taken for 1 hour, 50 times for dregs of a decoction A weight of each solvent load, filtration obtain dregs of a decoction B and extract B, and extract B is reclaimed Ethanol, is concentrated into relative density 1.12, and filtration, liquid are first washed with water, then use weight by XAD-4 large pore resin absorption columns 83% ethanol solution of percent concentration elutes XAD-4 large pore resin absorption columns, collects 83% ethanol eluate of weight percent concentration, Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 2：Pharmaceutical composition for the treatment of optic atrophy and preparation method thereof
Treatment optic atrophy pharmaceutical composition bulk drug composition and weight portion be：Wolf beanstalk grass 922g japanese spicebush bark 590g Asiatic acid 15g wood tangerine 168g black bones are galloped along on horseback 65g；
Preparation method：
（1）Wolf beanstalk grass, japanese spicebush bark, asiatic acid, wooden tangerine, black bone are taken by bulk drug proportioning to gallop along on horseback, is mixed, it is dense with percentage by weight 36.5% ethanol being spent as solvent, being taken in 24.5 DEG C of temperature extractions, extraction time is 12 times, and each extraction time is 0.4 hour, often 27 times for bulk drug gross weight of secondary solvent load, filtration obtain dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into phase To density 1.04, filtration, liquid are first washed with water by H103 large pore resin absorption columns, then with 19% second of weight percent concentration Alcoholic solution elutes H103 large pore resin absorption columns, collects 19% ethanol eluate of weight percent concentration, reclaims ethanol, and concentration is dry It is dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with 78% ethanol of weight percent concentration as solvent, heating and refluxing extraction 5 times, is carried every time The time is taken for 1 hour, 50 times for dregs of a decoction A weight of each solvent load, filtration obtain dregs of a decoction B and extract B, and extract B is reclaimed Ethanol, is concentrated into relative density 1.12, and filtration, liquid are first washed with water, then use weight by XAD-4 large pore resin absorption columns 83% ethanol solution of percent concentration elutes XAD-4 large pore resin absorption columns, collects 83% ethanol eluate of weight percent concentration, Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 3：Pharmaceutical composition for the treatment of optic atrophy and preparation method thereof
Treatment optic atrophy pharmaceutical composition bulk drug composition and weight portion be：Wolf beanstalk grass 928g japanese spicebush bark 582g Asiatic acid 17g wood tangerine 162g black bones are galloped along on horseback 70g；
Preparation method：
（1）Wolf beanstalk grass, japanese spicebush bark, asiatic acid, wooden tangerine, black bone are taken by bulk drug proportioning to gallop along on horseback, is mixed, it is dense with percentage by weight 36.5% ethanol being spent as solvent, being taken in 24.5 DEG C of temperature extractions, extraction time is 12 times, and each extraction time is 0.4 hour, often 27 times for bulk drug gross weight of secondary solvent load, filtration obtain dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into phase To density 1.04, filtration, liquid are first washed with water by H103 large pore resin absorption columns, then with 19% second of weight percent concentration Alcoholic solution elutes H103 large pore resin absorption columns, collects 19% ethanol eluate of weight percent concentration, reclaims ethanol, and concentration is dry It is dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with 78% ethanol of weight percent concentration as solvent, heating and refluxing extraction 5 times, is carried every time The time is taken for 1 hour, 50 times for dregs of a decoction A weight of each solvent load, filtration obtain dregs of a decoction B and extract B, and extract B is reclaimed Ethanol, is concentrated into relative density 1.12, and filtration, liquid are first washed with water, then use weight by XAD-4 large pore resin absorption columns 83% ethanol solution of percent concentration elutes XAD-4 large pore resin absorption columns, collects 83% ethanol eluate of weight percent concentration, Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 4：The preparation of tablet
1 pharmaceutical composition 364g of Example, adds starch 450g, mixes, and granulation is dried, plus microcrystalline cellulose 118g, stearic Sour magnesium 15g, mixes, is pressed into 3000, obtains final product medicinal composition tablets.
Embodiment 5：The preparation of capsule
2 pharmaceutical composition 345g of Example, adds starch 550g, mixes, and granulation is dried, whole grain, adds appropriate stearic acid Magnesium, mixes, encapsulated 2000, obtains final product medicament composition capsule.
Embodiment 6：The preparation of dripping pill
Weigh (80 DEG C) heating of Macrogol 6000 80g water-baths and boil molten, add 3 pharmaceutical composition 3g of embodiment, be sufficiently stirred for Uniformly, with atoleine as cooling agent, put glass tube（4*80cm）In, chilling temperature is 5 DEG C, and drip internal-and external diameter is 7.0/2.0 (mm/mm), drip is 2.6cm away from liquid level, and drop speed is per dividing 48 drops as optimum condition, to blot the condensation on dripping pill surface with cotton Agent, obtains final product medicament composition dropping pills.
Experimental example 1：The experimental study for the treatment of optic atrophy
1. clinical data
The Eye injuries that this city hospital accepts for medical treatment 2 months～in March, 2012 in 2011 cause optic atrophy 30, are randomly divided into and control Treatment group and control group, 15 26 eyes for the treatment of group, 15 26 eyes of control group.Wherein treatment group is male 8, female 7, right eye 11 Example, left eye 15,16～54 years old age, the course of disease 2 months～14 years.Traumatogenic reason：Boxing injury, traffic accident are stabbed, and are wounded, Damage；Control group man 8, female 7, right eye 11, left eye 15,16～53 years old age, the course of disease 2 months～13 years.Cause injury original Cause：Boxing injury, traffic accident are stabbed, and are wounded, and are damaged.Two groups of patients compare no difference of science of statistics in physical data（P ＞ 0.05）, with comparativity.
2. treatment method
Control group adopts western medicine, the Ai Luming parenteral solution retrobulbar injections of 130mg, interval 1d can be adopted to inject once, 1 treatment Journey is 25 times, is treated after 10d again, and the main points of retrobulbar injection were ensured that the week of drug injection to optic nerve accurately Enclose, should also add after injection with inosine, atriphos and vitamins etc..Treatment group is on the basis for the treatment of of control group scheme Upper addition treatment by Chinese herbs, with invigorating spleen for diuresis, promoting blood circulation and removing blood stasis as treatment method, using pharmaceutical composition（1 drug regimen of embodiment Thing）Orally, each 1.4g, 3 times a day.
3. criterion of therapeutical effect
It is effective：By light sensation, no light perception, index, manual and 0.02 each behavior sequence, eyesight improves three rows and the visual field is more than 20 degree of patient.Effectively：Patient's vision improves three rows, improves 0.2 after being calculated using logarithm eyesight, while the visual field Expand the patient more than 10 degree.It is invalid：The eyesight of patient and the visual field are not improved.
4. statistical method
This group of data are analyzed and are processed using SPSS12.0 statistics softwares, and enumeration data adopts Chi-square Test, metering money Material is checked using t, and P ＜ 0.05 have statistical significance for difference.
5. treatment results
After 26 eyes for the treatment of group are treated using the method for the combination of Chinese tradiational and Western medicine, there are 11 eyes effective, 13 eyes are effective, 2 Eye is invalid, and total effective rate is 92.31%, and the eyesight of patient improves more than 3 rows, the enlarging amplitude in the visual field also 20 degree with On.Control group has 7 eyes effective, and effectively, 11 eyes are invalid, and total effective rate is 57.69% for 8 eyes.Two groups of Comparison of therapeutic have aobvious Sex differernce is write, with statistical significance（P ＜ 0.05）.

Claims (8)

1. a kind of pharmaceutical composition for treating optic atrophy, it is characterised in that make the composition of the bulk drug of the pharmaceutical composition With weight portion it is：
Wolf beanstalk grass 922-928 weight portion japanese spicebush bark 582-590 weight portion asiatic acid 15-17 weight portions wood tangerine 162-168 weights Amount part black bone is galloped along on horseback 65-70 weight portions.
2. a kind of pharmaceutical composition for treating optic atrophy according to claim 1, it is characterised in that make the medicine group The composition and weight portion of the bulk drug of compound be：
16 weight portion wood 165 weight portion black bone of tangerine of wolf beanstalk grass 925 weight portion japanese spicebush bark 586 weight portion asiatic acid gallops along on horseback 68 Weight portion.
3. a kind of pharmaceutical composition for treating optic atrophy according to claim 1, it is characterised in that pharmaceutical composition can Piece agent or capsule or dripping pill are prepared with the conventional method using galenic pharmacy.
4. a kind of pharmaceutical composition for treating optic atrophy according to claim 1, it is characterised in that pharmaceutical composition with The treatment optic atrophy medicine of chemical drugs or Chinese medicine composition.
5. a kind of preparation method of the pharmaceutical composition for treating optic atrophy, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：Wolf beanstalk grass 922-928 weight portion japanese spicebush bark 582-590 weight portion asiatic acids 15-17 weight portions wood tangerine 162-168 weight portion black bones are galloped along on horseback 65-70 weight portions；
Preparation method：
（1）Wolf beanstalk grass, japanese spicebush bark, asiatic acid, wooden tangerine, black bone are taken by bulk drug proportioning to gallop along on horseback, is mixed, it is dense with percentage by weight 36.5% ethanol being spent as solvent, being taken in 24.5 DEG C of temperature extractions, extraction time is 12 times, and each extraction time is 0.4 hour, often 27 times for bulk drug gross weight of secondary solvent load, filtration obtain dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into phase To density 1.04, filtration, liquid are first washed with water by H103 large pore resin absorption columns, then with 19% second of weight percent concentration Alcoholic solution elutes H103 large pore resin absorption columns, collects 19% ethanol eluate of weight percent concentration, reclaims ethanol, and concentration is dry It is dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with 78% ethanol of weight percent concentration as solvent, heating and refluxing extraction 5 times, is carried every time The time is taken for 1 hour, 50 times for dregs of a decoction A weight of each solvent load, filtration obtain dregs of a decoction B and extract B, and extract B is reclaimed Ethanol, is concentrated into relative density 1.12, and filtration, liquid are first washed with water, then use weight by XAD-4 large pore resin absorption columns 83% ethanol solution of percent concentration elutes XAD-4 large pore resin absorption columns, collects 83% ethanol eluate of weight percent concentration, Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
6. a kind of preparation method of the pharmaceutical composition for treating optic atrophy according to claim 5, it is characterised in that press It is prepared by following steps：
The composition and weight portion of bulk drug be：586 weight portion asiatic acid of wolf beanstalk 925 weight portion japanese spicebush bark of grass, 16 weight portion 165 weight portion black bone of wooden tangerine is galloped along on horseback 68 weight portions；
Preparation method：
（1）Wolf beanstalk grass, japanese spicebush bark, asiatic acid, wooden tangerine, black bone are taken by bulk drug proportioning to gallop along on horseback, is mixed, it is dense with percentage by weight 36.5% ethanol being spent as solvent, being taken in 24.5 DEG C of temperature extractions, extraction time is 12 times, and each extraction time is 0.4 hour, often 27 times for bulk drug gross weight of secondary solvent load, filtration obtain dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into phase To density 1.04, filtration, liquid are first washed with water by H103 large pore resin absorption columns, then with 19% second of weight percent concentration Alcoholic solution elutes H103 large pore resin absorption columns, collects 19% ethanol eluate of weight percent concentration, reclaims ethanol, and concentration is dry It is dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with 78% ethanol of weight percent concentration as solvent, heating and refluxing extraction 5 times, is carried every time The time is taken for 1 hour, 50 times for dregs of a decoction A weight of each solvent load, filtration obtain dregs of a decoction B and extract B, and extract B is reclaimed Ethanol, is concentrated into relative density 1.12, and filtration, liquid are first washed with water, then use weight by XAD-4 large pore resin absorption columns 83% ethanol solution of percent concentration elutes XAD-4 large pore resin absorption columns, collects 83% ethanol eluate of weight percent concentration, Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
7. a kind of preparation method of the pharmaceutical composition for treating optic atrophy according to claim 5, it is characterised in that medicine Compositions can adopt the conventional method of galenic pharmacy to prepare piece agent or capsule or dripping pill.
8. a kind of preparation method of the pharmaceutical composition for treating optic atrophy according to claim 5, it is characterised in that medicine Compositions and chemical drugs or Chinese medicine composition treatment optic atrophy medicine.
CN201611133177.4A 2016-12-10 2016-12-10 A kind of pharmaceutical composition for treating optic atrophy Withdrawn CN106539934A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611133177.4A CN106539934A (en) 2016-12-10 2016-12-10 A kind of pharmaceutical composition for treating optic atrophy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611133177.4A CN106539934A (en) 2016-12-10 2016-12-10 A kind of pharmaceutical composition for treating optic atrophy

Publications (1)

Publication Number Publication Date
CN106539934A true CN106539934A (en) 2017-03-29

Family

ID=58397010

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611133177.4A Withdrawn CN106539934A (en) 2016-12-10 2016-12-10 A kind of pharmaceutical composition for treating optic atrophy

Country Status (1)

Country Link
CN (1) CN106539934A (en)

Similar Documents

Publication Publication Date Title
CN101496844B (en) External preparation for treating leukoderma and method for preparing and using the same
CN102813780A (en) Chinese herbal medicinal compound preparation used for treating macular degeneration of old people and preparation method thereof
CN102614413B (en) Chinese medicinal composition for treating sinusitis in children and preparation method thereof
CN103520643B (en) A kind of Chinese medicine preparation being used for the treatment of diabetic cataract and preparation method thereof
CN106539934A (en) A kind of pharmaceutical composition for treating optic atrophy
CN103251725B (en) A kind of application of Chinese medicine composition in treatment keratitis medicine is prepared
CN107582633B (en) External traditional Chinese medicine preparation for treating urticaria and preparation method thereof
CN104983972A (en) Hordeolum treatment drop and preparation method thereof
CN106619816A (en) Pharmaceutical composition for treating optic atrophy
CN104523962A (en) Radix morindae officinalis health maintenance traditional Chinese medicine wine and preparation method
CN104622987B (en) A kind of pharmaceutical composition for treating chronic hepatitis liver cirrhosis and application
CN104324139B (en) A kind of pharmaceutical composition treating xerophthalmia
CN106619754A (en) Medicine compound for treating glaucoma
CN106344730A (en) Traditional Chinese medicine composition for treating neonatal jaundice and preparation method thereof
CN106728299A (en) It is a kind of to treat pharmaceutical composition of protrusion of lumber intervertebral disc and preparation method thereof
CN104173808B (en) A kind of Chinese medicine and preparation method thereof for treating flaming-up of the liverfire type hypertension
CN106540027A (en) It is a kind of to prevent and treat pharmaceutical composition of laryngitis and preparation method thereof
CN106620269A (en) Pharmaceutical composition for preventing and treating vitreous opacity and preparation method thereof
CN106728014A (en) Treat Chinese medicine composition of eye keratitis and preparation method thereof
CN106581263A (en) Pharmaceutical composition for treating lumbar disc herniation and preparation method thereof
CN107854626A (en) A kind of medicinal liquor of relaxing tendons and activating collaterals and preparation method thereof
CN106511642A (en) Pharmaceutical composition preventing diabetic retinopathy and preparation method for pharmaceutical composition
CN106692502A (en) Medicinal composition for preventing and treating optic atrophy
CN106668336A (en) Pharmaceutical composition for treating otitis media
CN108653586A (en) A kind of Chinese medicine composition is preparing the application in treating anti-parkinson drug

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20170329

WW01 Invention patent application withdrawn after publication